|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 38/26 | (2006.01) |
| A61K 38/26 | (2013.01) | ||
| A61P 1/00 | (2006.01) | ||
| A61P 1/00 | (2018.01) |
| (11) | Number of the document | 3881861 |
| (13) | Kind of document | T |
| (96) | European patent application number | 21150552.4 |
| Date of filing the European patent application | 2018-06-15 | |
| (97) | Date of publication of the European application | 2021-09-22 |
| (45) | Date of publication and mention of the grant of the patent | 2024-07-31 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 201709643 | 2017-06-16 | GB | |
| 201714203 | 2017-09-05 | GB | |
| 201800873 | 2018-01-19 | GB |
| (72) |
Sonne, Kim , DK
Mouritzen, Ulrik , DK
Glerup, Peter , DK
Jeppesen, Palle Bekker , DK
|
| (73) |
Zealand Pharma A/S ,
Sydmarken 11, 2860 Søborg,
DK
|
| (54) | DOSAGE REGIMES FOR THE ADMINISTRATION OF GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES |
| DOSAGE REGIMES FOR THE ADMINISTRATION OF GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES |